retatrutide new zealand (LY3437943) | GCGR/GIPR/GLP-1R Agonist Retatrutide Dosage Guide 2026: Phase

Vzquez-Manrique RP, Farina F, Cambon K, et al

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome

Common physical changes patients describe after GLP-1-supported weight loss include: Looser skin around the abdomen, flanks, and lower back Sagging or bat wing tissue along the upper arms Thigh skin that appears crepey or hangs when sitting or standing Decreased fullness in the breasts or buttocks Less volume in the face, particularly the cheeks and under the eyes These changes can feel surprising

Smaller Biotechs and Collaborators: Companies like Zealand Pharma, Glycadia, and others have GLP-1 analogs or co-agonists in early trials, often in partnership with larger pharma (e.g., Novo Nordisk collaboration with Zealand)